... and down to 12.50, basically straight down from ~30 in less than two weeks. (MTSR)
Nothing has changed about their prospects except the ability to finance in this market and the price they could sell themselves for, as with many other biotech. That and investors not wanting to hold spec positions or need to deleverage.
There are opportunities out there but the uncertainties and risks remain.
Market Data 
Markets 
AI
